Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CALML3 | P27482 | 1/20 | 0.44 |
| ▸ | FADS1 | O60427 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12356902 | 1.00 | GRM2 (0.54) | GRM2SIRT1MAOAMAOBHPGD | |
| SCHEMBL2832723 | 0.86 | GRM2 (0.55) | GRM2SIRT1HPGDTSHR | |
| SCHEMBL11744593 | 0.86 | GRM2 (0.63) | GRM2SIRT1HPGDTSHR | |
| SCHEMBL2836661 | 0.86 | GRM2 (0.55) | GRM2SIRT1HPGDTSHR | |
| SCHEMBL15757602 | 0.85 | MAPK1 (0.46) | GRM2MAOAMAOBHPGDCALML3 | |
| SCHEMBL20485430 | 0.85 | GRM2 (0.45) | GRM2MAOAMAOB | |
| SCHEMBL15758259 | 0.85 | MAOA (0.49) | GRM2MAOAMAOB | |
| SCHEMBL15757524 | 0.85 | GRM2 (0.60) | GRM2CALML3FADS1 | |
| SCHEMBL14662038 | 0.85 | MAPK1 (0.46) | GRM2MAOAMAOBHPGDCALML3 | |
| SCHEMBL1972447 | 0.85 | MAPK1 (0.46) | GRM2MAOAMAOBHPGDCALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8183782-A | — | — | None | — | — | JP | disclosed |
| CN-112409286-B | Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | 杭州迪克科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-112409286-A | Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | 杭州迪克科技有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-9464062-B2 | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464062-B2 | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464062-B2 | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150291539-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-10-15 | — | — | US | disclosed |
| US-20150291539-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-10-15 | — | — | US | disclosed |
| US-20150291539-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-10-15 | — | — | US | disclosed |
| WO-2014085413-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-06-05 | — | — | WO | disclosed |
| JP-H08183782-A | METHOD FOR CRYSTALLIZING 4-BENZYL-5-HYDROXYMETHYLOXAZOLIDIN-2-ONE | KANEGAFUCHI CHEM IND CO LTD | 1996-07-16 | — | — | JP | disclosed |
| US-4886794-A | ANTIHISTAMINES, ANTIALLERGENS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0291244-A1 | Cyclic carbamate derivatives | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291539-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | HTR2B, TPH2, HTR2C | GRM2 77/4885SIRT1 2310/4885MAOA 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.